id	sid	tid	token	lemma	pos
dpc-2740	1	1	dermatology	dermatology	NOUN
dpc-2740	1	2	:	:	PUNCT
dpc-2740	1	3	practical	practical	ADJ
dpc-2740	1	4	and	and	CCONJ
dpc-2740	1	5	conceptual	conceptual	ADJ
dpc-2740	1	6	research	research	NOUN
dpc-2740	1	7	letter	letter	NOUN
dpc-2740	2	1	|	|	ADV
dpc-2740	2	2	dermatol	dermatol	ADJ
dpc-2740	2	3	pract	pract	NOUN
dpc-2740	2	4	concept	concept	NOUN
dpc-2740	2	5	.	.	PUNCT
dpc-2740	3	1	2023;13(2):e2023103	2023;13(2):e2023103	NUM
dpc-2740	3	2	1	1	NUM
dpc-2740	3	3	biologics	biologic	NOUN
dpc-2740	3	4	for	for	ADP
dpc-2740	3	5	the	the	DET
dpc-2740	3	6	treatment	treatment	NOUN
dpc-2740	3	7	of	of	ADP
dpc-2740	3	8	severe	severe	ADJ
dpc-2740	3	9	acrodermatitis	acrodermatitis	NOUN
dpc-2740	3	10	continua	continua	NOUN
dpc-2740	3	11	of	of	ADP
dpc-2740	3	12	hallopeau	hallopeau	PROPN
dpc-2740	3	13	:	:	PUNCT
dpc-2740	3	14	report	report	NOUN
dpc-2740	3	15	 	 	SPACE
dpc-2740	3	16	of	of	ADP
dpc-2740	3	17	 	 	SPACE
dpc-2740	3	18	two	two	NUM
dpc-2740	3	19	cases	case	NOUN
dpc-2740	3	20	successfully	successfully	ADV
dpc-2740	3	21	treated	treat	VERB
dpc-2740	3	22	with	with	ADP
dpc-2740	3	23	ixekizumab	ixekizumab	NOUN
dpc-2740	3	24	and	and	CCONJ
dpc-2740	3	25	ustekinumab	ustekinumab	NOUN
dpc-2740	3	26	luigi	luigi	PROPN
dpc-2740	3	27	gargiulo1,2	gargiulo1,2	PROPN
dpc-2740	3	28	,	,	PUNCT
dpc-2740	3	29	francesco	francesco	PROPN
dpc-2740	3	30	toso1,2	toso1,2	PROPN
dpc-2740	3	31	,	,	PUNCT
dpc-2740	3	32	luciano	luciano	PROPN
dpc-2740	3	33	ibba1,2	ibba1,2	PROPN
dpc-2740	3	34	,	,	PUNCT
dpc-2740	3	35	mario	mario	PROPN
dpc-2740	3	36	valenti1,2	valenti1,2	PROPN
dpc-2740	3	37	,	,	PUNCT
dpc-2740	3	38	antonio	antonio	PROPN
dpc-2740	3	39	costanzo1,2	costanzo1,2	PROPN
dpc-2740	3	40	,	,	PUNCT
dpc-2740	3	41	alessandra	alessandra	PROPN
dpc-2740	3	42	narcisi1,2	narcisi1,2	ADJ
dpc-2740	3	43	1	1	NUM
dpc-2740	3	44	dermatology	dermatology	NOUN
dpc-2740	3	45	unit	unit	NOUN
dpc-2740	3	46	,	,	PUNCT
dpc-2740	3	47	irccs	ircc	VERB
dpc-2740	3	48	humanitas	humanitas	NOUN
dpc-2740	3	49	research	research	NOUN
dpc-2740	3	50	hospital	hospital	NOUN
dpc-2740	3	51	,	,	PUNCT
dpc-2740	3	52	rozzano	rozzano	PROPN
dpc-2740	3	53	,	,	PUNCT
dpc-2740	3	54	milano	milano	PROPN
dpc-2740	3	55	,	,	PUNCT
dpc-2740	3	56	italy	italy	PROPN
dpc-2740	3	57	2	2	NUM
dpc-2740	3	58	department	department	NOUN
dpc-2740	3	59	of	of	ADP
dpc-2740	3	60	biomedical	biomedical	ADJ
dpc-2740	3	61	sciences	sciences	PROPN
dpc-2740	3	62	,	,	PUNCT
dpc-2740	3	63	humanitas	humanita	NOUN
dpc-2740	3	64	university	university	NOUN
dpc-2740	3	65	,	,	PUNCT
dpc-2740	3	66	pieve	pieve	PROPN
dpc-2740	3	67	emanuele	emanuele	PROPN
dpc-2740	3	68	,	,	PUNCT
dpc-2740	3	69	milano	milano	PROPN
dpc-2740	3	70	,	,	PUNCT
dpc-2740	3	71	italy	italy	PROPN
dpc-2740	3	72	key	key	ADJ
dpc-2740	3	73	words	word	NOUN
dpc-2740	3	74	:	:	PUNCT
dpc-2740	3	75	psoriasis	psoriasis	NOUN
dpc-2740	3	76	,	,	PUNCT
dpc-2740	3	77	acrodermatitis	acrodermatitis	NOUN
dpc-2740	3	78	continua	continua	NOUN
dpc-2740	3	79	of	of	ADP
dpc-2740	3	80	hallopeau	hallopeau	PROPN
dpc-2740	3	81	,	,	PUNCT
dpc-2740	3	82	ixekizumab	ixekizumab	NOUN
dpc-2740	3	83	,	,	PUNCT
dpc-2740	3	84	ustekinumab	ustekinumab	NOUN
dpc-2740	3	85	,	,	PUNCT
dpc-2740	3	86	biologics	biologic	NOUN
dpc-2740	3	87	citation	citation	NOUN
dpc-2740	3	88	:	:	PUNCT
dpc-2740	3	89	gargiulo	gargiulo	PROPN
dpc-2740	3	90	l	l	PROPN
dpc-2740	3	91	,	,	PUNCT
dpc-2740	3	92	toso	toso	PROPN
dpc-2740	3	93	f	f	X
dpc-2740	3	94	,	,	PUNCT
dpc-2740	3	95	ibba	ibba	PROPN
dpc-2740	3	96	l	l	NOUN
dpc-2740	3	97	,	,	PUNCT
dpc-2740	3	98	valenti	valenti	PROPN
dpc-2740	3	99	m	m	PROPN
dpc-2740	3	100	,	,	PUNCT
dpc-2740	3	101	costanzo	costanzo	PROPN
dpc-2740	3	102	a	a	DET
dpc-2740	3	103	,	,	PUNCT
dpc-2740	3	104	narcisi	narcisi	ADJ
dpc-2740	3	105	a.	a.	NOUN
dpc-2740	3	106	biologics	biologic	NOUN
dpc-2740	3	107	for	for	ADP
dpc-2740	3	108	the	the	DET
dpc-2740	3	109	treatment	treatment	NOUN
dpc-2740	3	110	of	of	ADP
dpc-2740	3	111	severe	severe	ADJ
dpc-2740	3	112	acrodermatitis	acrodermatitis	NOUN
dpc-2740	3	113	continua	continua	NOUN
dpc-2740	3	114	of	of	ADP
dpc-2740	3	115	hallopeau	hallopeau	PROPN
dpc-2740	3	116	:	:	PUNCT
dpc-2740	3	117	report	report	NOUN
dpc-2740	3	118	of	of	ADP
dpc-2740	3	119	two	two	NUM
dpc-2740	3	120	cases	case	NOUN
dpc-2740	3	121	successfully	successfully	ADV
dpc-2740	3	122	treated	treat	VERB
dpc-2740	3	123	with	with	ADP
dpc-2740	3	124	ixekizumab	ixekizumab	NOUN
dpc-2740	3	125	and	and	CCONJ
dpc-2740	3	126	ustekinumab	ustekinumab	NOUN
dpc-2740	3	127	.	.	PUNCT
dpc-2740	4	1	dermatol	dermatol	NOUN
dpc-2740	4	2	pract	pract	PROPN
dpc-2740	4	3	concept	concept	NOUN
dpc-2740	4	4	.	.	PUNCT
dpc-2740	5	1	2023;13(2):e2023103	2023;13(2):e2023103	X
dpc-2740	5	2	.	.	X
dpc-2740	6	1	doi	doi	NOUN
dpc-2740	6	2	:	:	PUNCT
dpc-2740	6	3	https://doi.org/10.5826/dpc.1302a103	https://doi.org/10.5826/dpc.1302a103	PROPN
dpc-2740	6	4	accepted	accept	VERB
dpc-2740	6	5	:	:	PUNCT
dpc-2740	6	6	september	september	PROPN
dpc-2740	6	7	26	26	NUM
dpc-2740	6	8	,	,	PUNCT
dpc-2740	6	9	2023	2023	NUM
dpc-2740	6	10	;	;	PUNCT
dpc-2740	6	11	published	publish	VERB
dpc-2740	6	12	:	:	PUNCT
dpc-2740	7	1	april	april	PROPN
dpc-2740	7	2	2023	2023	NUM
dpc-2740	7	3	copyright	copyright	NOUN
dpc-2740	7	4	:	:	PUNCT
dpc-2740	7	5	©	©	PROPN
dpc-2740	7	6	2023	2023	NUM
dpc-2740	7	7	gargiulo	gargiulo	NOUN
dpc-2740	7	8	et	et	PROPN
dpc-2740	7	9	al	al	PROPN
dpc-2740	7	10	.	.	PUNCT
dpc-2740	8	1	this	this	PRON
dpc-2740	8	2	is	be	AUX
dpc-2740	8	3	an	an	DET
dpc-2740	8	4	open	open	ADJ
dpc-2740	8	5	-	-	PUNCT
dpc-2740	8	6	access	access	NOUN
dpc-2740	8	7	article	article	NOUN
dpc-2740	8	8	distributed	distribute	VERB
dpc-2740	8	9	under	under	ADP
dpc-2740	8	10	the	the	DET
dpc-2740	8	11	terms	term	NOUN
dpc-2740	8	12	of	of	ADP
dpc-2740	8	13	the	the	DET
dpc-2740	8	14	creative	creative	ADJ
dpc-2740	8	15	commons	common	NOUN
dpc-2740	8	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-2740	8	17	license	license	NOUN
dpc-2740	8	18	(	(	PUNCT
dpc-2740	8	19	by	by	ADP
dpc-2740	8	20	-	-	PUNCT
dpc-2740	8	21	nc-4.0	nc-4.0	NOUN
dpc-2740	8	22	)	)	PUNCT
dpc-2740	8	23	,	,	PUNCT
dpc-2740	8	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-2740	8	25	,	,	PUNCT
dpc-2740	8	26	which	which	PRON
dpc-2740	8	27	permits	permit	VERB
dpc-2740	8	28	unrestricted	unrestricted	ADJ
dpc-2740	8	29	noncommercial	noncommercial	ADJ
dpc-2740	8	30	use	use	NOUN
dpc-2740	8	31	,	,	PUNCT
dpc-2740	8	32	distribution	distribution	NOUN
dpc-2740	8	33	,	,	PUNCT
dpc-2740	8	34	and	and	CCONJ
dpc-2740	8	35	reproduction	reproduction	NOUN
dpc-2740	8	36	in	in	ADP
dpc-2740	8	37	any	any	DET
dpc-2740	8	38	medium	medium	NOUN
dpc-2740	8	39	,	,	PUNCT
dpc-2740	8	40	provided	provide	VERB
dpc-2740	8	41	the	the	DET
dpc-2740	8	42	original	original	ADJ
dpc-2740	8	43	authors	author	NOUN
dpc-2740	8	44	and	and	CCONJ
dpc-2740	8	45	source	source	NOUN
dpc-2740	8	46	are	be	AUX
dpc-2740	8	47	credited	credit	VERB
dpc-2740	8	48	.	.	PUNCT
dpc-2740	9	1	funding	funding	NOUN
dpc-2740	9	2	:	:	PUNCT
dpc-2740	9	3	none	none	NOUN
dpc-2740	9	4	.	.	PUNCT
dpc-2740	10	1	competing	compete	VERB
dpc-2740	10	2	interests	interest	NOUN
dpc-2740	10	3	:	:	PUNCT
dpc-2740	10	4	antonio	antonio	PROPN
dpc-2740	10	5	costanzo	costanzo	PROPN
dpc-2740	10	6	has	have	AUX
dpc-2740	10	7	been	be	AUX
dpc-2740	10	8	a	a	DET
dpc-2740	10	9	consultant	consultant	NOUN
dpc-2740	10	10	and/or	and/or	CCONJ
dpc-2740	10	11	speaker	speaker	NOUN
dpc-2740	10	12	for	for	ADP
dpc-2740	10	13	abb	abb	PROPN
dpc-2740	10	14	-	-	PUNCT
dpc-2740	10	15	vie	vie	PROPN
dpc-2740	10	16	,	,	PUNCT
dpc-2740	10	17	almirall	almirall	ADJ
dpc-2740	10	18	,	,	PUNCT
dpc-2740	10	19	amgen	amgen	PROPN
dpc-2740	10	20	,	,	PUNCT
dpc-2740	10	21	janssen	janssen	PROPN
dpc-2740	10	22	,	,	PUNCT
dpc-2740	10	23	leo	leo	PROPN
dpc-2740	10	24	pharma	pharma	PROPN
dpc-2740	10	25	,	,	PUNCT
dpc-2740	10	26	eli	eli	PROPN
dpc-2740	10	27	lilly	lilly	PROPN
dpc-2740	10	28	,	,	PUNCT
dpc-2740	10	29	galderma	galderma	PROPN
dpc-2740	10	30	,	,	PUNCT
dpc-2740	10	31	boehringer	boehringer	NOUN
dpc-2740	10	32	,	,	PUNCT
dpc-2740	10	33	novartis	novartis	NOUN
dpc-2740	10	34	,	,	PUNCT
dpc-2740	10	35	pfizer	pfizer	NOUN
dpc-2740	10	36	,	,	PUNCT
dpc-2740	10	37	sandoz	sandoz	PROPN
dpc-2740	10	38	,	,	PUNCT
dpc-2740	10	39	and	and	CCONJ
dpc-2740	10	40	ucb	ucb	PROPN
dpc-2740	10	41	.	.	PUNCT
dpc-2740	11	1	alessandra	alessandra	PROPN
dpc-2740	11	2	narcisi	narcisi	PROPN
dpc-2740	11	3	has	have	AUX
dpc-2740	11	4	been	be	AUX
dpc-2740	11	5	a	a	DET
dpc-2740	11	6	consultant	consultant	NOUN
dpc-2740	11	7	and/or	and/or	CCONJ
dpc-2740	11	8	speaker	speaker	NOUN
dpc-2740	11	9	for	for	ADP
dpc-2740	11	10	abb	abb	PROPN
dpc-2740	11	11	-	-	PUNCT
dpc-2740	11	12	vie	vie	PROPN
dpc-2740	11	13	,	,	PUNCT
dpc-2740	11	14	almirall	almirall	ADJ
dpc-2740	11	15	,	,	PUNCT
dpc-2740	11	16	amgen	amgen	PROPN
dpc-2740	11	17	,	,	PUNCT
dpc-2740	11	18	janssen	janssen	PROPN
dpc-2740	11	19	,	,	PUNCT
dpc-2740	11	20	leo	leo	PROPN
dpc-2740	11	21	pharma	pharma	PROPN
dpc-2740	11	22	,	,	PUNCT
dpc-2740	11	23	eli	eli	PROPN
dpc-2740	11	24	lilly	lilly	PROPN
dpc-2740	11	25	,	,	PUNCT
dpc-2740	11	26	boehringer	boehringer	PROPN
dpc-2740	11	27	,	,	PUNCT
dpc-2740	11	28	novartis	novartis	NOUN
dpc-2740	11	29	,	,	PUNCT
dpc-2740	11	30	pfizer	pfizer	NOUN
dpc-2740	11	31	and	and	CCONJ
dpc-2740	11	32	ucb	ucb	PROPN
dpc-2740	11	33	.	.	PROPN
dpc-2740	12	1	mario	mario	PROPN
dpc-2740	12	2	valenti	valenti	PROPN
dpc-2740	12	3	has	have	AUX
dpc-2740	12	4	been	be	AUX
dpc-2740	12	5	a	a	DET
dpc-2740	12	6	consultant	consultant	NOUN
dpc-2740	12	7	and/or	and/or	CCONJ
dpc-2740	12	8	speaker	speaker	NOUN
dpc-2740	12	9	for	for	ADP
dpc-2740	12	10	,	,	PUNCT
dpc-2740	12	11	leo	leo	PROPN
dpc-2740	12	12	pharma	pharma	PROPN
dpc-2740	12	13	,	,	PUNCT
dpc-2740	12	14	eli	eli	PROPN
dpc-2740	12	15	lilly	lilly	PROPN
dpc-2740	12	16	,	,	PUNCT
dpc-2740	12	17	boehringer	boehringer	NOUN
dpc-2740	12	18	and	and	CCONJ
dpc-2740	12	19	sanofi	sanofi	PROPN
dpc-2740	12	20	.	.	PUNCT
dpc-2740	13	1	luigi	luigi	PROPN
dpc-2740	13	2	gargiulo	gargiulo	PROPN
dpc-2740	13	3	,	,	PUNCT
dpc-2740	13	4	francesco	francesco	PROPN
dpc-2740	13	5	toso	toso	PROPN
dpc-2740	13	6	and	and	CCONJ
dpc-2740	13	7	luciano	luciano	PROPN
dpc-2740	13	8	ibba	ibba	PROPN
dpc-2740	13	9	have	have	VERB
dpc-2740	13	10	nothing	nothing	PRON
dpc-2740	13	11	to	to	PART
dpc-2740	13	12	disclose	disclose	VERB
dpc-2740	13	13	.	.	PUNCT
dpc-2740	14	1	authorship	authorship	NOUN
dpc-2740	14	2	:	:	PUNCT
dpc-2740	14	3	all	all	DET
dpc-2740	14	4	authors	author	NOUN
dpc-2740	14	5	have	have	AUX
dpc-2740	14	6	contributed	contribute	VERB
dpc-2740	14	7	significantly	significantly	ADV
dpc-2740	14	8	to	to	ADP
dpc-2740	14	9	this	this	DET
dpc-2740	14	10	publication	publication	NOUN
dpc-2740	14	11	.	.	PUNCT
dpc-2740	15	1	corresponding	correspond	VERB
dpc-2740	15	2	author	author	NOUN
dpc-2740	15	3	:	:	PUNCT
dpc-2740	15	4	dr	dr	PROPN
dpc-2740	15	5	.	.	PROPN
dpc-2740	15	6	francesco	francesco	PROPN
dpc-2740	15	7	toso	toso	PROPN
dpc-2740	15	8	,	,	PUNCT
dpc-2740	15	9	md	md	PROPN
dpc-2740	15	10	,	,	PUNCT
dpc-2740	15	11	dermatology	dermatology	NOUN
dpc-2740	15	12	unit	unit	NOUN
dpc-2740	15	13	,	,	PUNCT
dpc-2740	15	14	department	department	NOUN
dpc-2740	15	15	of	of	ADP
dpc-2740	15	16	biomedical	biomedical	ADJ
dpc-2740	15	17	sciences	sciences	PROPN
dpc-2740	15	18	irccs	ircc	VERB
dpc-2740	15	19	humanitas	humanitas	NOUN
dpc-2740	15	20	research	research	NOUN
dpc-2740	15	21	hospital	hospital	NOUN
dpc-2740	15	22	,	,	PUNCT
dpc-2740	15	23	humanitas	humanitas	X
dpc-2740	15	24	university	university	NOUN
dpc-2740	15	25	,	,	PUNCT
dpc-2740	15	26	rozzano	rozzano	PROPN
dpc-2740	15	27	(	(	PUNCT
dpc-2740	15	28	mi	mi	PROPN
dpc-2740	15	29	)	)	PUNCT
dpc-2740	15	30	,	,	PUNCT
dpc-2740	15	31	italy	italy	PROPN
dpc-2740	15	32	.	.	PUNCT
dpc-2740	16	1	tel	tel	ADP
dpc-2740	16	2	:	:	PUNCT
dpc-2740	16	3	+39	+39	PROPN
dpc-2740	16	4	0282244050	0282244050	NUM
dpc-2740	16	5	email	email	NOUN
dpc-2740	16	6	:	:	PUNCT
dpc-2740	16	7	francesco.toso@humanitas.it	francesco.toso@humanitas.it	PROPN
dpc-2740	16	8	introduction	introduction	NOUN
dpc-2740	16	9	acrodermatitis	acrodermatitis	NOUN
dpc-2740	16	10	continua	continua	PROPN
dpc-2740	16	11	of	of	ADP
dpc-2740	16	12	hallopeau	hallopeau	PROPN
dpc-2740	16	13	(	(	PUNCT
dpc-2740	16	14	ach	ach	PROPN
dpc-2740	16	15	)	)	PUNCT
dpc-2740	16	16	is	be	AUX
dpc-2740	16	17	a	a	DET
dpc-2740	16	18	rare	rare	ADJ
dpc-2740	16	19	form	form	NOUN
dpc-2740	16	20	of	of	ADP
dpc-2740	16	21	pustular	pustular	ADJ
dpc-2740	16	22	psoriasis	psoriasis	NOUN
dpc-2740	16	23	,	,	PUNCT
dpc-2740	16	24	which	which	PRON
dpc-2740	16	25	involves	involve	VERB
dpc-2740	16	26	the	the	DET
dpc-2740	16	27	distal	distal	ADJ
dpc-2740	16	28	portion	portion	NOUN
dpc-2740	16	29	of	of	ADP
dpc-2740	16	30	the	the	DET
dpc-2740	16	31	digits	digit	NOUN
dpc-2740	16	32	of	of	ADP
dpc-2740	16	33	hands	hand	NOUN
dpc-2740	16	34	and	and	CCONJ
dpc-2740	16	35	feet	foot	NOUN
dpc-2740	17	1	[	[	X
dpc-2740	17	2	1	1	NUM
dpc-2740	17	3	]	]	PUNCT
dpc-2740	17	4	.	.	PUNCT
dpc-2740	18	1	the	the	DET
dpc-2740	18	2	exact	exact	ADJ
dpc-2740	18	3	pathogenesis	pathogenesis	NOUN
dpc-2740	18	4	of	of	ADP
dpc-2740	18	5	this	this	DET
dpc-2740	18	6	disease	disease	NOUN
dpc-2740	18	7	is	be	AUX
dpc-2740	18	8	still	still	ADV
dpc-2740	18	9	not	not	PART
dpc-2740	18	10	completely	completely	ADV
dpc-2740	18	11	understood	understand	VERB
dpc-2740	18	12	,	,	PUNCT
dpc-2740	18	13	and	and	CCONJ
dpc-2740	18	14	a	a	DET
dpc-2740	18	15	role	role	NOUN
dpc-2740	18	16	of	of	ADP
dpc-2740	18	17	interleukin	interleukin	NOUN
dpc-2740	18	18	(	(	PUNCT
dpc-2740	18	19	il)-36	il)-36	PROPN
dpc-2740	18	20	and	and	CCONJ
dpc-2740	18	21	il-17	il-17	ADV
dpc-2740	18	22	related	related	ADJ
dpc-2740	18	23	cytokines	cytokine	NOUN
dpc-2740	18	24	(	(	PUNCT
dpc-2740	18	25	il-17a	il-17a	PROPN
dpc-2740	18	26	/	/	SYM
dpc-2740	18	27	f	f	PROPN
dpc-2740	18	28	,	,	PUNCT
dpc-2740	18	29	il23receptor	il23receptor	PROPN
dpc-2740	18	30	)	)	PUNCT
dpc-2740	18	31	has	have	AUX
dpc-2740	18	32	been	be	AUX
dpc-2740	18	33	proposed	propose	VERB
dpc-2740	18	34	[	[	X
dpc-2740	18	35	1	1	NUM
dpc-2740	18	36	]	]	PUNCT
dpc-2740	18	37	.	.	PUNCT
dpc-2740	19	1	ach	ach	PROPN
dpc-2740	19	2	has	have	VERB
dpc-2740	19	3	a	a	DET
dpc-2740	19	4	chronic	chronic	NOUN
dpc-2740	19	5	-	-	PUNCT
dpc-2740	19	6	relapsing	relapse	VERB
dpc-2740	19	7	course	course	NOUN
dpc-2740	19	8	,	,	PUNCT
dpc-2740	19	9	and	and	CCONJ
dpc-2740	19	10	it	it	PRON
dpc-2740	19	11	can	can	AUX
dpc-2740	19	12	lead	lead	VERB
dpc-2740	19	13	to	to	ADP
dpc-2740	19	14	severe	severe	ADJ
dpc-2740	19	15	nail	nail	NOUN
dpc-2740	19	16	dystrophies	dystrophy	NOUN
dpc-2740	19	17	[	[	X
dpc-2740	19	18	1	1	NUM
dpc-2740	19	19	]	]	PUNCT
dpc-2740	19	20	.	.	PUNCT
dpc-2740	20	1	given	give	VERB
dpc-2740	20	2	the	the	DET
dpc-2740	20	3	rarity	rarity	NOUN
dpc-2740	20	4	of	of	ADP
dpc-2740	20	5	this	this	DET
dpc-2740	20	6	condition	condition	NOUN
dpc-2740	20	7	,	,	PUNCT
dpc-2740	20	8	no	no	DET
dpc-2740	20	9	data	datum	NOUN
dpc-2740	20	10	are	be	AUX
dpc-2740	20	11	available	available	ADJ
dpc-2740	20	12	from	from	ADP
dpc-2740	20	13	clinical	clinical	ADJ
dpc-2740	20	14	trials	trial	NOUN
dpc-2740	20	15	regarding	regard	VERB
dpc-2740	20	16	the	the	DET
dpc-2740	20	17	use	use	NOUN
dpc-2740	20	18	of	of	ADP
dpc-2740	20	19	biological	biological	ADJ
dpc-2740	20	20	drugs	drug	NOUN
dpc-2740	20	21	in	in	ADP
dpc-2740	20	22	these	these	DET
dpc-2740	20	23	patients	patient	NOUN
dpc-2740	20	24	[	[	X
dpc-2740	20	25	1,2	1,2	NUM
dpc-2740	20	26	]	]	PUNCT
dpc-2740	20	27	.	.	PUNCT
dpc-2740	21	1	we	we	PRON
dpc-2740	21	2	present	present	VERB
dpc-2740	21	3	two	two	NUM
dpc-2740	21	4	cases	case	NOUN
dpc-2740	21	5	of	of	ADP
dpc-2740	21	6	severe	severe	ADJ
dpc-2740	21	7	ach	ach	PROPN
dpc-2740	21	8	successfully	successfully	ADV
dpc-2740	21	9	treated	treat	VERB
dpc-2740	21	10	with	with	ADP
dpc-2740	21	11	biologics	biologic	NOUN
dpc-2740	21	12	:	:	PUNCT
dpc-2740	21	13	one	one	NUM
dpc-2740	21	14	patient	patient	NOUN
dpc-2740	21	15	received	receive	VERB
dpc-2740	21	16	ixekizumab	ixekizumab	NOUN
dpc-2740	21	17	,	,	PUNCT
dpc-2740	21	18	a	a	DET
dpc-2740	21	19	humanized	humanize	VERB
dpc-2740	21	20	monoclonal	monoclonal	NOUN
dpc-2740	21	21	antibody	antibody	NOUN
dpc-2740	21	22	targeting	target	VERB
dpc-2740	21	23	il-17a	il-17a	PROPN
dpc-2740	21	24	,	,	PUNCT
dpc-2740	21	25	and	and	CCONJ
dpc-2740	21	26	the	the	DET
dpc-2740	21	27	second	second	ADJ
dpc-2740	21	28	was	be	AUX
dpc-2740	21	29	given	give	VERB
dpc-2740	21	30	ustekinumab	ustekinumab	NOUN
dpc-2740	21	31	,	,	PUNCT
dpc-2740	21	32	an	an	DET
dpc-2740	21	33	inhibitor	inhibitor	NOUN
dpc-2740	21	34	of	of	ADP
dpc-2740	21	35	il-12/23	il-12/23	PROPN
dpc-2740	21	36	.	.	PROPN
dpc-2740	21	37	case	case	NOUN
dpc-2740	21	38	presentation	presentation	NOUN
dpc-2740	21	39	a	a	DET
dpc-2740	21	40	56	56	NUM
dpc-2740	21	41	-	-	PUNCT
dpc-2740	21	42	year	year	NOUN
dpc-2740	21	43	-	-	PUNCT
dpc-2740	21	44	old	old	ADJ
dpc-2740	21	45	patient	patient	NOUN
dpc-2740	21	46	presented	present	VERB
dpc-2740	21	47	to	to	ADP
dpc-2740	21	48	our	our	PRON
dpc-2740	21	49	dermatology	dermatology	NOUN
dpc-2740	21	50	department	department	NOUN
dpc-2740	21	51	with	with	ADP
dpc-2740	21	52	a	a	DET
dpc-2740	21	53	history	history	NOUN
dpc-2740	21	54	of	of	ADP
dpc-2740	21	55	psoriasis	psoriasis	NOUN
dpc-2740	21	56	and	and	CCONJ
dpc-2740	21	57	psoriatic	psoriatic	ADJ
dpc-2740	21	58	arthritis	arthritis	NOUN
dpc-2740	21	59	(	(	PUNCT
dpc-2740	21	60	psa	psa	NOUN
dpc-2740	21	61	)	)	PUNCT
dpc-2740	21	62	,	,	PUNCT
dpc-2740	21	63	with	with	ADP
dpc-2740	21	64	a	a	DET
dpc-2740	21	65	dermatology	dermatology	NOUN
dpc-2740	21	66	life	life	NOUN
dpc-2740	21	67	quality	quality	NOUN
dpc-2740	21	68	index	index	NOUN
dpc-2740	21	69	(	(	PUNCT
dpc-2740	21	70	dlqi	dlqi	ADJ
dpc-2740	21	71	)	)	PUNCT
dpc-2740	21	72	score	score	NOUN
dpc-2740	21	73	of	of	ADP
dpc-2740	21	74	28	28	NUM
dpc-2740	21	75	.	.	PUNCT
dpc-2740	22	1	in	in	ADP
dpc-2740	22	2	the	the	DET
dpc-2740	22	3	past	past	NOUN
dpc-2740	22	4	,	,	PUNCT
dpc-2740	22	5	she	she	PRON
dpc-2740	22	6	was	be	AUX
dpc-2740	22	7	treated	treat	VERB
dpc-2740	22	8	with	with	ADP
dpc-2740	22	9	oral	oral	ADJ
dpc-2740	22	10	acitretin	acitretin	NOUN
dpc-2740	22	11	10	10	NUM
dpc-2740	22	12	mg	mg	PROPN
dpc-2740	22	13	,	,	PUNCT
dpc-2740	22	14	one	one	NUM
dpc-2740	22	15	capsule	capsule	NOUN
dpc-2740	22	16	daily	daily	ADV
dpc-2740	22	17	for	for	ADP
dpc-2740	22	18	3	3	NUM
dpc-2740	22	19	months	month	NOUN
dpc-2740	22	20	,	,	PUNCT
dpc-2740	22	21	ineffectively	ineffectively	ADV
dpc-2740	22	22	.	.	PUNCT
dpc-2740	23	1	on	on	ADP
dpc-2740	23	2	clinical	clinical	ADJ
dpc-2740	23	3	examination	examination	NOUN
dpc-2740	23	4	,	,	PUNCT
dpc-2740	23	5	we	we	PRON
dpc-2740	23	6	observed	observe	VERB
dpc-2740	23	7	intense	intense	ADJ
dpc-2740	23	8	red	red	ADJ
dpc-2740	23	9	erythema	erythema	NOUN
dpc-2740	23	10	on	on	ADP
dpc-2740	23	11	the	the	DET
dpc-2740	23	12	distal	distal	ADJ
dpc-2740	23	13	surface	surface	NOUN
dpc-2740	23	14	of	of	ADP
dpc-2740	23	15	the	the	DET
dpc-2740	23	16	five	five	NUM
dpc-2740	23	17	fingers	finger	NOUN
dpc-2740	23	18	of	of	ADP
dpc-2740	23	19	the	the	DET
dpc-2740	23	20	right	right	ADJ
dpc-2740	23	21	foot	foot	NOUN
dpc-2740	23	22	,	,	PUNCT
dpc-2740	23	23	along	along	ADP
dpc-2740	23	24	with	with	ADP
dpc-2740	23	25	intense	intense	ADJ
dpc-2740	23	26	pustulation	pustulation	NOUN
dpc-2740	23	27	and	and	CCONJ
dpc-2740	23	28	severe	severe	ADJ
dpc-2740	23	29	onychopathy	onychopathy	ADJ
dpc-2740	23	30	(	(	PUNCT
dpc-2740	23	31	figure	figure	NOUN
dpc-2740	23	32	1a	1a	NOUN
dpc-2740	23	33	)	)	PUNCT
dpc-2740	23	34	,	,	PUNCT
dpc-2740	23	35	2	2	NUM
dpc-2740	23	36	research	research	NOUN
dpc-2740	23	37	letter	letter	NOUN
dpc-2740	23	38	|	|	ADV
dpc-2740	23	39	dermatol	dermatol	ADJ
dpc-2740	23	40	pract	pract	NOUN
dpc-2740	23	41	concept	concept	NOUN
dpc-2740	23	42	.	.	PUNCT
dpc-2740	24	1	2023;13(2):e2023103	2023;13(2):e2023103	NUM
dpc-2740	24	2	and	and	CCONJ
dpc-2740	24	3	moderate	moderate	ADJ
dpc-2740	24	4	erythema	erythema	NOUN
dpc-2740	24	5	and	and	CCONJ
dpc-2740	24	6	onychopathy	onychopathy	ADJ
dpc-2740	24	7	on	on	ADP
dpc-2740	24	8	the	the	DET
dpc-2740	24	9	left	left	ADJ
dpc-2740	24	10	foot	foot	NOUN
dpc-2740	24	11	(	(	PUNCT
dpc-2740	24	12	figure	figure	NOUN
dpc-2740	24	13	 	 	SPACE
dpc-2740	24	14	1b	1b	NUM
dpc-2740	24	15	)	)	PUNCT
dpc-2740	24	16	.	.	PUNCT
dpc-2740	25	1	a	a	DET
dpc-2740	25	2	skin	skin	NOUN
dpc-2740	25	3	biopsy	biopsy	NOUN
dpc-2740	25	4	was	be	AUX
dpc-2740	25	5	not	not	PART
dpc-2740	25	6	performed	perform	VERB
dpc-2740	25	7	as	as	ADP
dpc-2740	25	8	the	the	DET
dpc-2740	25	9	clinical	clinical	ADJ
dpc-2740	25	10	picture	picture	NOUN
dpc-2740	25	11	was	be	AUX
dpc-2740	25	12	strongly	strongly	ADV
dpc-2740	25	13	suggestive	suggestive	ADJ
dpc-2740	25	14	for	for	ADP
dpc-2740	25	15	ach	ach	PROPN
dpc-2740	25	16	.	.	PUNCT
dpc-2740	26	1	given	give	VERB
dpc-2740	26	2	the	the	DET
dpc-2740	26	3	severity	severity	NOUN
dpc-2740	26	4	of	of	ADP
dpc-2740	26	5	the	the	DET
dpc-2740	26	6	clinical	clinical	ADJ
dpc-2740	26	7	picture	picture	NOUN
dpc-2740	26	8	,	,	PUNCT
dpc-2740	26	9	as	as	SCONJ
dpc-2740	26	10	screening	screen	VERB
dpc-2740	26	11	exams	exam	NOUN
dpc-2740	26	12	were	be	AUX
dpc-2740	26	13	all	all	ADV
dpc-2740	26	14	in	in	ADP
dpc-2740	26	15	the	the	DET
dpc-2740	26	16	normal	normal	ADJ
dpc-2740	26	17	ranges	range	NOUN
dpc-2740	26	18	,	,	PUNCT
dpc-2740	26	19	we	we	PRON
dpc-2740	26	20	prescribed	prescribe	VERB
dpc-2740	26	21	therapy	therapy	NOUN
dpc-2740	26	22	with	with	ADP
dpc-2740	26	23	ixekizumab	ixekizumab	NOUN
dpc-2740	26	24	80	80	NUM
dpc-2740	26	25	 	 	SPACE
dpc-2740	26	26	mg	mg	PROPN
dpc-2740	26	27	,	,	PUNCT
dpc-2740	26	28	two	two	NUM
dpc-2740	26	29	injections	injection	NOUN
dpc-2740	26	30	at	at	ADP
dpc-2740	26	31	baseline	baseline	NOUN
dpc-2740	26	32	followed	follow	VERB
dpc-2740	26	33	by	by	ADP
dpc-2740	26	34	one	one	NUM
dpc-2740	26	35	injection	injection	NOUN
dpc-2740	26	36	every	every	DET
dpc-2740	26	37	two	two	NUM
dpc-2740	26	38	weeks	week	NOUN
dpc-2740	26	39	until	until	ADP
dpc-2740	26	40	week	week	NOUN
dpc-2740	26	41	12	12	NUM
dpc-2740	26	42	,	,	PUNCT
dpc-2740	26	43	and	and	CCONJ
dpc-2740	26	44	then	then	ADV
dpc-2740	26	45	every	every	DET
dpc-2740	26	46	four	four	NUM
dpc-2740	26	47	weeks	week	NOUN
dpc-2740	26	48	.	.	PUNCT
dpc-2740	27	1	at	at	ADP
dpc-2740	27	2	week	week	NOUN
dpc-2740	27	3	36	36	NUM
dpc-2740	27	4	,	,	PUNCT
dpc-2740	27	5	the	the	DET
dpc-2740	27	6	patient	patient	NOUN
dpc-2740	27	7	came	come	VERB
dpc-2740	27	8	back	back	ADV
dpc-2740	27	9	to	to	ADP
dpc-2740	27	10	our	our	PRON
dpc-2740	27	11	department	department	NOUN
dpc-2740	27	12	showing	show	VERB
dpc-2740	27	13	complete	complete	ADJ
dpc-2740	27	14	skin	skin	NOUN
dpc-2740	27	15	clearance	clearance	NOUN
dpc-2740	27	16	,	,	PUNCT
dpc-2740	27	17	with	with	ADP
dpc-2740	27	18	the	the	DET
dpc-2740	27	19	persistence	persistence	NOUN
dpc-2740	27	20	of	of	ADP
dpc-2740	27	21	only	only	ADJ
dpc-2740	27	22	slight	slight	ADJ
dpc-2740	27	23	onychopathy	onychopathy	ADJ
dpc-2740	27	24	(	(	PUNCT
dpc-2740	27	25	figure	figure	NOUN
dpc-2740	27	26	2	2	NUM
dpc-2740	27	27	,	,	PUNCT
dpc-2740	27	28	a	a	PRON
dpc-2740	27	29	and	and	CCONJ
dpc-2740	27	30	b	b	NOUN
dpc-2740	27	31	)	)	PUNCT
dpc-2740	27	32	and	and	CCONJ
dpc-2740	27	33	a	a	DET
dpc-2740	27	34	dlqi	dlqi	NOUN
dpc-2740	27	35	of	of	ADP
dpc-2740	27	36	1	1	NUM
dpc-2740	27	37	.	.	PUNCT
dpc-2740	28	1	the	the	DET
dpc-2740	28	2	second	second	ADJ
dpc-2740	28	3	patient	patient	NOUN
dpc-2740	28	4	is	be	AUX
dpc-2740	28	5	a	a	DET
dpc-2740	28	6	32	32	NUM
dpc-2740	28	7	-	-	PUNCT
dpc-2740	28	8	year	year	NOUN
dpc-2740	28	9	-	-	PUNCT
dpc-2740	28	10	old	old	ADJ
dpc-2740	28	11	female	female	NOUN
dpc-2740	28	12	,	,	PUNCT
dpc-2740	28	13	who	who	PRON
dpc-2740	28	14	presented	present	VERB
dpc-2740	28	15	to	to	ADP
dpc-2740	28	16	our	our	PRON
dpc-2740	28	17	institute	institute	NOUN
dpc-2740	28	18	in	in	ADP
dpc-2740	28	19	2016	2016	NUM
dpc-2740	28	20	with	with	ADP
dpc-2740	28	21	a	a	DET
dpc-2740	28	22	history	history	NOUN
dpc-2740	28	23	of	of	ADP
dpc-2740	28	24	flares	flare	NOUN
dpc-2740	28	25	of	of	ADP
dpc-2740	28	26	ach	ach	PROPN
dpc-2740	28	27	(	(	PUNCT
dpc-2740	28	28	with	with	ADP
dpc-2740	28	29	fever	fever	NOUN
dpc-2740	28	30	and	and	CCONJ
dpc-2740	28	31	elevated	elevated	ADJ
dpc-2740	28	32	neutrophils	neutrophil	NOUN
dpc-2740	28	33	count	count	NOUN
dpc-2740	28	34	)	)	PUNCT
dpc-2740	28	35	,	,	PUNCT
dpc-2740	28	36	previously	previously	ADV
dpc-2740	28	37	ineffectively	ineffectively	ADV
dpc-2740	28	38	treated	treat	VERB
dpc-2740	28	39	with	with	ADP
dpc-2740	28	40	oral	oral	ADJ
dpc-2740	28	41	cyclosporine	cyclosporine	NOUN
dpc-2740	28	42	.	.	PUNCT
dpc-2740	29	1	on	on	ADP
dpc-2740	29	2	physical	physical	ADJ
dpc-2740	29	3	examination	examination	NOUN
dpc-2740	29	4	,	,	PUNCT
dpc-2740	29	5	several	several	ADJ
dpc-2740	29	6	pustules	pustule	NOUN
dpc-2740	29	7	on	on	ADP
dpc-2740	29	8	erythematous	erythematous	ADJ
dpc-2740	29	9	skin	skin	NOUN
dpc-2740	29	10	were	be	AUX
dpc-2740	29	11	observed	observe	VERB
dpc-2740	29	12	on	on	ADP
dpc-2740	29	13	the	the	DET
dpc-2740	29	14	distal	distal	ADJ
dpc-2740	29	15	surface	surface	NOUN
dpc-2740	29	16	of	of	ADP
dpc-2740	29	17	the	the	DET
dpc-2740	29	18	fingers	finger	NOUN
dpc-2740	29	19	of	of	ADP
dpc-2740	29	20	both	both	DET
dpc-2740	29	21	hands	hand	NOUN
dpc-2740	29	22	.	.	PUNCT
dpc-2740	30	1	subsequently	subsequently	ADV
dpc-2740	30	2	,	,	PUNCT
dpc-2740	30	3	after	after	ADP
dpc-2740	30	4	screening	screen	VERB
dpc-2740	30	5	exams	exam	NOUN
dpc-2740	30	6	returned	return	VERB
dpc-2740	30	7	all	all	ADV
dpc-2740	30	8	in	in	ADP
dpc-2740	30	9	the	the	DET
dpc-2740	30	10	normal	normal	ADJ
dpc-2740	30	11	ranges	range	NOUN
dpc-2740	30	12	,	,	PUNCT
dpc-2740	30	13	we	we	PRON
dpc-2740	30	14	prescribed	prescribe	VERB
dpc-2740	30	15	ustekinumab	ustekinumab	NOUN
dpc-2740	30	16	45	45	NUM
dpc-2740	30	17	mg	mg	NOUN
dpc-2740	30	18	,	,	PUNCT
dpc-2740	30	19	1	1	NUM
dpc-2740	30	20	injection	injection	NOUN
dpc-2740	30	21	at	at	ADP
dpc-2740	30	22	weeks	week	NOUN
dpc-2740	30	23	0	0	NUM
dpc-2740	30	24	,	,	PUNCT
dpc-2740	30	25	4	4	NUM
dpc-2740	30	26	,	,	PUNCT
dpc-2740	30	27	and	and	CCONJ
dpc-2740	30	28	then	then	ADV
dpc-2740	30	29	every	every	DET
dpc-2740	30	30	12	12	NUM
dpc-2740	30	31	weeks	week	NOUN
dpc-2740	30	32	.	.	PUNCT
dpc-2740	31	1	at	at	ADP
dpc-2740	31	2	week	week	NOUN
dpc-2740	31	3	40	40	NUM
dpc-2740	31	4	,	,	PUNCT
dpc-2740	31	5	the	the	DET
dpc-2740	31	6	patient	patient	NOUN
dpc-2740	31	7	showed	show	VERB
dpc-2740	31	8	complete	complete	ADJ
dpc-2740	31	9	skin	skin	NOUN
dpc-2740	31	10	clearance	clearance	NOUN
dpc-2740	31	11	.	.	PUNCT
dpc-2740	32	1	she	she	PRON
dpc-2740	32	2	is	be	AUX
dpc-2740	32	3	still	still	ADV
dpc-2740	32	4	on	on	ADP
dpc-2740	32	5	treatment	treatment	NOUN
dpc-2740	32	6	to	to	ADP
dpc-2740	32	7	date	date	NOUN
dpc-2740	32	8	,	,	PUNCT
dpc-2740	32	9	without	without	ADP
dpc-2740	32	10	any	any	DET
dpc-2740	32	11	relapse	relapse	NOUN
dpc-2740	32	12	of	of	ADP
dpc-2740	32	13	the	the	DET
dpc-2740	32	14	disease	disease	NOUN
dpc-2740	32	15	.	.	PUNCT
dpc-2740	33	1	conclusions	conclusion	NOUN
dpc-2740	33	2	the	the	DET
dpc-2740	33	3	treatment	treatment	NOUN
dpc-2740	33	4	of	of	ADP
dpc-2740	33	5	ach	ach	PROPN
dpc-2740	33	6	is	be	AUX
dpc-2740	33	7	challenging	challenge	VERB
dpc-2740	33	8	,	,	PUNCT
dpc-2740	33	9	due	due	ADP
dpc-2740	33	10	to	to	ADP
dpc-2740	33	11	the	the	DET
dpc-2740	33	12	lack	lack	NOUN
dpc-2740	33	13	of	of	ADP
dpc-2740	33	14	randomized	randomized	ADJ
dpc-2740	33	15	clinical	clinical	ADJ
dpc-2740	33	16	trials	trial	NOUN
dpc-2740	33	17	on	on	ADP
dpc-2740	33	18	biological	biological	ADJ
dpc-2740	33	19	drugs	drug	NOUN
dpc-2740	33	20	,	,	PUNCT
dpc-2740	33	21	given	give	VERB
dpc-2740	33	22	the	the	DET
dpc-2740	33	23	rarity	rarity	NOUN
dpc-2740	33	24	of	of	ADP
dpc-2740	33	25	this	this	DET
dpc-2740	33	26	condition	condition	NOUN
dpc-2740	34	1	[	[	X
dpc-2740	34	2	2	2	NUM
dpc-2740	34	3	]	]	PUNCT
dpc-2740	34	4	.	.	PUNCT
dpc-2740	35	1	there	there	PRON
dpc-2740	35	2	are	be	VERB
dpc-2740	35	3	only	only	ADV
dpc-2740	35	4	a	a	DET
dpc-2740	35	5	few	few	ADJ
dpc-2740	35	6	case	case	NOUN
dpc-2740	35	7	reports	report	NOUN
dpc-2740	35	8	on	on	ADP
dpc-2740	35	9	the	the	DET
dpc-2740	35	10	efficacy	efficacy	NOUN
dpc-2740	35	11	of	of	ADP
dpc-2740	35	12	ixekizumab	ixekizumab	NOUN
dpc-2740	35	13	in	in	ADP
dpc-2740	35	14	the	the	DET
dpc-2740	35	15	treatment	treatment	NOUN
dpc-2740	35	16	of	of	ADP
dpc-2740	35	17	pustular	pustular	ADJ
dpc-2740	35	18	variants	variant	NOUN
dpc-2740	35	19	of	of	ADP
dpc-2740	35	20	psoriasis	psoriasis	NOUN
dpc-2740	35	21	[	[	X
dpc-2740	35	22	3	3	NUM
dpc-2740	35	23	]	]	PUNCT
dpc-2740	35	24	.	.	PUNCT
dpc-2740	36	1	in	in	ADP
dpc-2740	36	2	our	our	PRON
dpc-2740	36	3	first	first	ADJ
dpc-2740	36	4	case	case	NOUN
dpc-2740	36	5	,	,	PUNCT
dpc-2740	36	6	we	we	PRON
dpc-2740	36	7	prescribed	prescribe	VERB
dpc-2740	36	8	ixekizumab	ixekizumab	NOUN
dpc-2740	36	9	for	for	ADP
dpc-2740	36	10	several	several	ADJ
dpc-2740	36	11	reason	reason	NOUN
dpc-2740	36	12	:	:	PUNCT
dpc-2740	36	13	the	the	DET
dpc-2740	36	14	rapid	rapid	ADJ
dpc-2740	36	15	onset	onset	NOUN
dpc-2740	36	16	of	of	ADP
dpc-2740	36	17	action	action	NOUN
dpc-2740	36	18	,	,	PUNCT
dpc-2740	36	19	the	the	DET
dpc-2740	36	20	efficacy	efficacy	NOUN
dpc-2740	36	21	on	on	ADP
dpc-2740	36	22	psa	psa	NOUN
dpc-2740	36	23	and	and	CCONJ
dpc-2740	36	24	our	our	PRON
dpc-2740	36	25	favorable	favorable	ADJ
dpc-2740	36	26	experience	experience	NOUN
dpc-2740	36	27	on	on	ADP
dpc-2740	36	28	this	this	DET
dpc-2740	36	29	drug	drug	NOUN
dpc-2740	36	30	on	on	ADP
dpc-2740	36	31	difficult	difficult	ADJ
dpc-2740	36	32	-	-	PUNCT
dpc-2740	36	33	to	to	ADP
dpc-2740	36	34	-	-	PUNCT
dpc-2740	36	35	treat	treat	NOUN
dpc-2740	36	36	areas	area	NOUN
dpc-2740	36	37	[	[	X
dpc-2740	36	38	4,5	4,5	NUM
dpc-2740	36	39	]	]	PUNCT
dpc-2740	36	40	.	.	PUNCT
dpc-2740	37	1	on	on	ADP
dpc-2740	37	2	the	the	DET
dpc-2740	37	3	other	other	ADJ
dpc-2740	37	4	hand	hand	NOUN
dpc-2740	37	5	,	,	PUNCT
dpc-2740	37	6	more	more	ADJ
dpc-2740	37	7	data	datum	NOUN
dpc-2740	37	8	are	be	AUX
dpc-2740	37	9	available	available	ADJ
dpc-2740	37	10	on	on	ADP
dpc-2740	37	11	ustekinumab	ustekinumab	NOUN
dpc-2740	37	12	in	in	ADP
dpc-2740	37	13	patients	patient	NOUN
dpc-2740	37	14	affected	affect	VERB
dpc-2740	37	15	by	by	ADP
dpc-2740	37	16	ach	ach	PROPN
dpc-2740	38	1	[	[	X
dpc-2740	38	2	6	6	NUM
dpc-2740	38	3	]	]	PUNCT
dpc-2740	38	4	.	.	PUNCT
dpc-2740	39	1	in	in	ADP
dpc-2740	39	2	a	a	DET
dpc-2740	39	3	multicenter	multicenter	ADJ
dpc-2740	39	4	retrospective	retrospective	ADJ
dpc-2740	39	5	study	study	NOUN
dpc-2740	39	6	,	,	PUNCT
dpc-2740	39	7	ustekinumab	ustekinumab	NOUN
dpc-2740	39	8	showed	show	VERB
dpc-2740	39	9	improvement	improvement	NOUN
dpc-2740	39	10	in	in	ADP
dpc-2740	39	11	75.0	75.0	NUM
dpc-2740	39	12	%	%	NOUN
dpc-2740	39	13	of	of	ADP
dpc-2740	39	14	patients	patient	NOUN
dpc-2740	39	15	[	[	X
dpc-2740	39	16	6	6	NUM
dpc-2740	39	17	]	]	PUNCT
dpc-2740	39	18	.	.	PUNCT
dpc-2740	40	1	in	in	ADP
dpc-2740	40	2	our	our	PRON
dpc-2740	40	3	case	case	NOUN
dpc-2740	40	4	,	,	PUNCT
dpc-2740	40	5	we	we	PRON
dpc-2740	40	6	decided	decide	VERB
dpc-2740	40	7	to	to	PART
dpc-2740	40	8	prescribe	prescribe	VERB
dpc-2740	40	9	ustekinumab	ustekinumab	NOUN
dpc-2740	40	10	because	because	SCONJ
dpc-2740	40	11	at	at	ADP
dpc-2740	40	12	the	the	DET
dpc-2740	40	13	time	time	NOUN
dpc-2740	40	14	it	it	PRON
dpc-2740	40	15	was	be	AUX
dpc-2740	40	16	the	the	DET
dpc-2740	40	17	most	most	ADV
dpc-2740	40	18	recent	recent	ADJ
dpc-2740	40	19	and	and	CCONJ
dpc-2740	40	20	most	most	ADV
dpc-2740	40	21	effective	effective	ADJ
dpc-2740	40	22	biological	biological	ADJ
dpc-2740	40	23	drug	drug	NOUN
dpc-2740	40	24	approved	approve	VERB
dpc-2740	40	25	for	for	ADP
dpc-2740	40	26	psoriasis	psoriasis	NOUN
dpc-2740	40	27	.	.	PUNCT
dpc-2740	41	1	further	further	ADJ
dpc-2740	41	2	studies	study	NOUN
dpc-2740	41	3	,	,	PUNCT
dpc-2740	41	4	with	with	ADP
dpc-2740	41	5	longitudinal	longitudinal	ADJ
dpc-2740	41	6	design	design	NOUN
dpc-2740	41	7	and	and	CCONJ
dpc-2740	41	8	larger	large	ADJ
dpc-2740	41	9	cohorts	cohort	NOUN
dpc-2740	41	10	of	of	ADP
dpc-2740	41	11	patients	patient	NOUN
dpc-2740	41	12	,	,	PUNCT
dpc-2740	41	13	are	be	AUX
dpc-2740	41	14	needed	need	VERB
dpc-2740	41	15	to	to	PART
dpc-2740	41	16	establish	establish	VERB
dpc-2740	41	17	the	the	DET
dpc-2740	41	18	exact	exact	ADJ
dpc-2740	41	19	role	role	NOUN
dpc-2740	41	20	of	of	ADP
dpc-2740	41	21	biologics	biologic	NOUN
dpc-2740	41	22	,	,	PUNCT
dpc-2740	41	23	including	include	VERB
dpc-2740	41	24	ustekinumab	ustekinumab	NOUN
dpc-2740	41	25	and	and	CCONJ
dpc-2740	41	26	ixekizumab	ixekizumab	NOUN
dpc-2740	41	27	,	,	PUNCT
dpc-2740	41	28	in	in	ADP
dpc-2740	41	29	the	the	DET
dpc-2740	41	30	management	management	NOUN
dpc-2740	41	31	of	of	ADP
dpc-2740	41	32	ach	ach	PROPN
dpc-2740	41	33	.	.	PUNCT
dpc-2740	42	1	ba	ba	PROPN
dpc-2740	42	2	figure	figure	NOUN
dpc-2740	42	3	1	1	NUM
dpc-2740	42	4	.	.	PUNCT
dpc-2740	43	1	(	(	PUNCT
dpc-2740	43	2	a	a	X
dpc-2740	43	3	)	)	PUNCT
dpc-2740	43	4	severe	severe	ADJ
dpc-2740	43	5	acrodermatitis	acrodermatitis	NOUN
dpc-2740	43	6	continua	continua	NOUN
dpc-2740	43	7	of	of	ADP
dpc-2740	43	8	hallopeau	hallopeau	NOUN
dpc-2740	43	9	affecting	affect	VERB
dpc-2740	43	10	the	the	DET
dpc-2740	43	11	digits	digit	NOUN
dpc-2740	43	12	of	of	ADP
dpc-2740	43	13	the	the	DET
dpc-2740	43	14	right	right	ADJ
dpc-2740	43	15	foot	foot	NOUN
dpc-2740	43	16	of	of	ADP
dpc-2740	43	17	a	a	DET
dpc-2740	43	18	56	56	NUM
dpc-2740	43	19	-	-	PUNCT
dpc-2740	43	20	year	year	NOUN
dpc-2740	43	21	-	-	PUNCT
dpc-2740	43	22	old	old	ADJ
dpc-2740	43	23	patient	patient	NOUN
dpc-2740	43	24	,	,	PUNCT
dpc-2740	43	25	with	with	ADP
dpc-2740	43	26	intense	intense	ADJ
dpc-2740	43	27	pustulation	pustulation	NOUN
dpc-2740	43	28	on	on	ADP
dpc-2740	43	29	erythematous	erythematous	ADJ
dpc-2740	43	30	skin	skin	NOUN
dpc-2740	43	31	along	along	ADP
dpc-2740	43	32	with	with	ADP
dpc-2740	43	33	severe	severe	ADJ
dpc-2740	43	34	psoriatic	psoriatic	ADJ
dpc-2740	43	35	onychopathy	onychopathy	NOUN
dpc-2740	43	36	.	.	PUNCT
dpc-2740	44	1	(	(	PUNCT
dpc-2740	44	2	b	b	X
dpc-2740	44	3	)	)	PUNCT
dpc-2740	44	4	clinical	clinical	ADJ
dpc-2740	44	5	appearance	appearance	NOUN
dpc-2740	44	6	of	of	ADP
dpc-2740	44	7	the	the	DET
dpc-2740	44	8	left	left	ADJ
dpc-2740	44	9	foot	foot	NOUN
dpc-2740	44	10	.	.	PUNCT
dpc-2740	45	1	research	research	NOUN
dpc-2740	45	2	letter	letter	NOUN
dpc-2740	45	3	|	|	ADV
dpc-2740	45	4	dermatol	dermatol	ADJ
dpc-2740	45	5	pract	pract	NOUN
dpc-2740	45	6	concept	concept	NOUN
dpc-2740	45	7	.	.	PUNCT
dpc-2740	46	1	2023;13(2):e2023103	2023;13(2):e2023103	NUM
dpc-2740	46	2	3	3	NUM
dpc-2740	46	3	references	reference	NOUN
dpc-2740	46	4	1	1	NUM
dpc-2740	46	5	.	.	PUNCT
dpc-2740	46	6	navarini	navarini	ADJ
dpc-2740	46	7	aa	aa	NOUN
dpc-2740	46	8	,	,	PUNCT
dpc-2740	46	9	burden	burden	NOUN
dpc-2740	46	10	ad	ad	NOUN
dpc-2740	46	11	,	,	PUNCT
dpc-2740	46	12	capon	capon	NOUN
dpc-2740	46	13	f	f	PROPN
dpc-2740	46	14	,	,	PUNCT
dpc-2740	46	15	et	et	PROPN
dpc-2740	46	16	al	al	PROPN
dpc-2740	46	17	.	.	PUNCT
dpc-2740	47	1	european	european	ADJ
dpc-2740	47	2	consensus	consensus	NOUN
dpc-2740	47	3	statement	statement	NOUN
dpc-2740	47	4	on	on	ADP
dpc-2740	47	5	phenotypes	phenotype	NOUN
dpc-2740	47	6	of	of	ADP
dpc-2740	47	7	pustular	pustular	ADJ
dpc-2740	47	8	psoriasis	psoriasis	NOUN
dpc-2740	47	9	.	.	PUNCT
dpc-2740	48	1	j	j	PROPN
dpc-2740	48	2	eur	eur	PROPN
dpc-2740	48	3	acad	acad	PROPN
dpc-2740	48	4	dermatol	dermatol	NOUN
dpc-2740	48	5	venereol	venereol	NOUN
dpc-2740	48	6	.	.	PUNCT
dpc-2740	49	1	2017;31(11):1792	2017;31(11):1792	NUM
dpc-2740	49	2	-	-	SYM
dpc-2740	49	3	1799	1799	NUM
dpc-2740	49	4	.	.	PUNCT
dpc-2740	50	1	doi:10.1111	doi:10.1111	ADJ
dpc-2740	50	2	/	/	SYM
dpc-2740	50	3	jdv	jdv	NOUN
dpc-2740	50	4	.14386	.14386	PROPN
dpc-2740	50	5	.	.	PUNCT
dpc-2740	51	1	pmid	pmid	NOUN
dpc-2740	51	2	:	:	PUNCT
dpc-2740	51	3	28585342	28585342	NUM
dpc-2740	51	4	.	.	X
dpc-2740	52	1	2	2	X
dpc-2740	52	2	.	.	X
dpc-2740	52	3	maliyar	maliyar	PROPN
dpc-2740	52	4	k	k	PROPN
dpc-2740	52	5	,	,	PUNCT
dpc-2740	52	6	crowley	crowley	PROPN
dpc-2740	52	7	el	el	PROPN
dpc-2740	52	8	,	,	PUNCT
dpc-2740	52	9	rodriguez	rodriguez	NOUN
dpc-2740	52	10	-	-	PUNCT
dpc-2740	52	11	bolanos	bolanos	PROPN
dpc-2740	52	12	f	f	NOUN
dpc-2740	52	13	,	,	PUNCT
dpc-2740	52	14	o’toole	o’toole	PROPN
dpc-2740	52	15	a	a	NOUN
dpc-2740	52	16	,	,	PUNCT
dpc-2740	52	17	gooderham	gooderham	PROPN
dpc-2740	52	18	mj	mj	PROPN
dpc-2740	52	19	.	.	PUNCT
dpc-2740	53	1	the	the	DET
dpc-2740	53	2	use	use	NOUN
dpc-2740	53	3	of	of	ADP
dpc-2740	53	4	biologic	biologic	NOUN
dpc-2740	53	5	therapy	therapy	NOUN
dpc-2740	53	6	in	in	ADP
dpc-2740	53	7	the	the	DET
dpc-2740	53	8	treatment	treatment	NOUN
dpc-2740	53	9	of	of	ADP
dpc-2740	53	10	acrodermatitis	acrodermatitis	NOUN
dpc-2740	53	11	continua	continua	PROPN
dpc-2740	53	12	of	of	ADP
dpc-2740	53	13	hallopeau	hallopeau	PROPN
dpc-2740	53	14	:	:	PUNCT
dpc-2740	53	15	a	a	DET
dpc-2740	53	16	review	review	NOUN
dpc-2740	53	17	.	.	PUNCT
dpc-2740	54	1	j	j	PROPN
dpc-2740	54	2	cutan	cutan	PROPN
dpc-2740	54	3	med	med	ADJ
dpc-2740	54	4	surg	surg	NOUN
dpc-2740	54	5	.	.	PUNCT
dpc-2740	55	1	2019;23(4):428	2019;23(4):428	NUM
dpc-2740	55	2	-	-	SYM
dpc-2740	55	3	435	435	NUM
dpc-2740	55	4	.	.	PUNCT
dpc-2740	55	5	doi:10.1177/1203475419836435	doi:10.1177/1203475419836435	VERB
dpc-2740	55	6	.	.	PUNCT
dpc-2740	56	1	pmid	pmid	NOUN
dpc-2740	56	2	:	:	PUNCT
dpc-2740	56	3	30938189	30938189	NUM
dpc-2740	56	4	.	.	PUNCT
dpc-2740	57	1	3	3	X
dpc-2740	57	2	.	.	X
dpc-2740	57	3	miller	miller	PROPN
dpc-2740	57	4	ac	ac	PROPN
dpc-2740	57	5	,	,	PUNCT
dpc-2740	57	6	holland	holland	PROPN
dpc-2740	57	7	te	te	PROPN
dpc-2740	57	8	,	,	PUNCT
dpc-2740	57	9	cohen	cohen	PROPN
dpc-2740	57	10	dj	dj	PROPN
dpc-2740	57	11	.	.	PUNCT
dpc-2740	57	12	treatment	treatment	NOUN
dpc-2740	57	13	of	of	ADP
dpc-2740	57	14	acrodermatitis	acrodermatitis	NOUN
dpc-2740	57	15	continua	continua	PROPN
dpc-2740	57	16	of	of	ADP
dpc-2740	57	17	hallopeau	hallopeau	NOUN
dpc-2740	57	18	with	with	ADP
dpc-2740	57	19	ixekizumab	ixekizumab	NOUN
dpc-2740	57	20	.	.	PUNCT
dpc-2740	58	1	j	j	PROPN
dpc-2740	58	2	dermatolog	dermatolog	PROPN
dpc-2740	58	3	treat	treat	NOUN
dpc-2740	58	4	.	.	PUNCT
dpc-2740	59	1	2021;32(1):117	2021;32(1):117	NUM
dpc-2740	59	2	-	-	PUNCT
dpc-2740	59	3	119	119	NUM
dpc-2740	59	4	.	.	PUNCT
dpc-2740	60	1	doi:10.1080/09546634.2019.1628170	doi:10.1080/09546634.2019.1628170	PROPN
dpc-2740	60	2	.	.	PUNCT
dpc-2740	61	1	pmid	pmid	NOUN
dpc-2740	61	2	:	:	PUNCT
dpc-2740	61	3	31184530	31184530	NUM
dpc-2740	61	4	.	.	PUNCT
dpc-2740	62	1	4	4	X
dpc-2740	62	2	.	.	NUM
dpc-2740	62	3	narcisi	narcisi	PROPN
dpc-2740	62	4	a	a	X
dpc-2740	62	5	,	,	PUNCT
dpc-2740	62	6	valenti	valenti	PROPN
dpc-2740	62	7	m	m	PROPN
dpc-2740	62	8	,	,	PUNCT
dpc-2740	62	9	cortese	cortese	PROPN
dpc-2740	62	10	a	a	X
dpc-2740	62	11	,	,	PUNCT
dpc-2740	62	12	et	et	PROPN
dpc-2740	62	13	al	al	PROPN
dpc-2740	62	14	.	.	PUNCT
dpc-2740	63	1	anti	anti	PROPN
dpc-2740	63	2	-	-	ADJ
dpc-2740	63	3	il17	il17	ADJ
dpc-2740	63	4	and	and	CCONJ
dpc-2740	63	5	anti	anti	ADJ
dpc-2740	63	6	-	-	ADJ
dpc-2740	63	7	il23	il23	ADJ
dpc-2740	63	8	biologic	biologic	NOUN
dpc-2740	63	9	drugs	drug	NOUN
dpc-2740	63	10	for	for	ADP
dpc-2740	63	11	scalp	scalp	NOUN
dpc-2740	63	12	psoriasis	psoriasis	NOUN
dpc-2740	63	13	:	:	PUNCT
dpc-2740	63	14	a	a	DET
dpc-2740	63	15	single	single	ADJ
dpc-2740	63	16	-	-	PUNCT
dpc-2740	63	17	center	center	NOUN
dpc-2740	63	18	retrospective	retrospective	ADJ
dpc-2740	63	19	comparative	comparative	ADJ
dpc-2740	63	20	study	study	NOUN
dpc-2740	63	21	.	.	PUNCT
dpc-2740	64	1	dermatol	dermatol	NOUN
dpc-2740	64	2	ther	ther	ADV
dpc-2740	64	3	.	.	PUNCT
dpc-2740	65	1	2022;35(2):e15228	2022;35(2):e15228	NUM
dpc-2740	65	2	.	.	PUNCT
dpc-2740	66	1	doi:10.1111	doi:10.1111	NOUN
dpc-2740	66	2	/	/	SYM
dpc-2740	66	3	dth.15228	dth.15228	PROPN
dpc-2740	66	4	pmid	pmid	PROPN
dpc-2740	66	5	:	:	PUNCT
dpc-2740	66	6	34820969	34820969	NUM
dpc-2740	66	7	.	.	PUNCT
dpc-2740	67	1	5	5	X
dpc-2740	67	2	.	.	X
dpc-2740	67	3	husson	husson	PROPN
dpc-2740	67	4	b	b	PROPN
dpc-2740	67	5	,	,	PUNCT
dpc-2740	67	6	barbe	barbe	PROPN
dpc-2740	67	7	c	c	X
dpc-2740	67	8	,	,	PUNCT
dpc-2740	67	9	hegazy	hegazy	PROPN
dpc-2740	67	10	s	s	PROPN
dpc-2740	67	11	,	,	PUNCT
dpc-2740	67	12	et	et	PROPN
dpc-2740	67	13	al	al	PROPN
dpc-2740	67	14	.	.	PROPN
dpc-2740	67	15	efficacy	efficacy	NOUN
dpc-2740	67	16	and	and	CCONJ
dpc-2740	67	17	safety	safety	NOUN
dpc-2740	67	18	of	of	ADP
dpc-2740	67	19	tnf	tnf	PROPN
dpc-2740	67	20	blockers	blocker	NOUN
dpc-2740	67	21	and	and	CCONJ
dpc-2740	67	22	of	of	ADP
dpc-2740	67	23	ustekinumab	ustekinumab	NOUN
dpc-2740	67	24	in	in	ADP
dpc-2740	67	25	palmoplantar	palmoplantar	NOUN
dpc-2740	67	26	pustulosis	pustulosis	NOUN
dpc-2740	67	27	and	and	CCONJ
dpc-2740	67	28	in	in	ADP
dpc-2740	67	29	acrodermatitis	acrodermatitis	NOUN
dpc-2740	67	30	continua	continua	PROPN
dpc-2740	67	31	of	of	ADP
dpc-2740	67	32	hallopeau	hallopeau	PROPN
dpc-2740	67	33	.	.	PUNCT
dpc-2740	68	1	j	j	PROPN
dpc-2740	68	2	eur	eur	PROPN
dpc-2740	68	3	acad	acad	PROPN
dpc-2740	68	4	dermatol	dermatol	NOUN
dpc-2740	68	5	venereol	venereol	NOUN
dpc-2740	68	6	.	.	PUNCT
dpc-2740	69	1	2020;34(10):2330	2020;34(10):2330	NUM
dpc-2740	69	2	-	-	SYM
dpc-2740	69	3	2338	2338	NUM
dpc-2740	69	4	.	.	PUNCT
dpc-2740	70	1	doi:10.1111	doi:10.1111	NOUN
dpc-2740	70	2	/	/	SYM
dpc-2740	70	3	jdv.16265	jdv.16265	X
dpc-2740	70	4	pmid	pmid	PROPN
dpc-2740	70	5	:	:	PUNCT
dpc-2740	70	6	32030802	32030802	NUM
dpc-2740	70	7	.	.	PUNCT
dpc-2740	71	1	6	6	NUM
dpc-2740	71	2	.	.	X
dpc-2740	71	3	gargiulo	gargiulo	PROPN
dpc-2740	71	4	l	l	NOUN
dpc-2740	71	5	,	,	PUNCT
dpc-2740	71	6	pavia	pavia	PROPN
dpc-2740	71	7	g	g	NOUN
dpc-2740	71	8	,	,	PUNCT
dpc-2740	71	9	ibba	ibba	PROPN
dpc-2740	71	10	l	l	NOUN
dpc-2740	71	11	,	,	PUNCT
dpc-2740	71	12	et	et	PROPN
dpc-2740	71	13	al	al	PROPN
dpc-2740	71	14	.	.	PROPN
dpc-2740	71	15	generalized	generalize	VERB
dpc-2740	71	16	pustular	pustular	ADJ
dpc-2740	71	17	psoriasis	psoriasis	NOUN
dpc-2740	71	18	and	and	CCONJ
dpc-2740	71	19	plaque	plaque	NOUN
dpc-2740	71	20	psoriasis	psoriasis	NOUN
dpc-2740	71	21	successfully	successfully	ADV
dpc-2740	71	22	treated	treat	VERB
dpc-2740	71	23	with	with	ADP
dpc-2740	71	24	ixekizumab	ixekizumab	NOUN
dpc-2740	71	25	.	.	PUNCT
dpc-2740	72	1	clin	clin	PROPN
dpc-2740	72	2	exp	exp	NOUN
dpc-2740	72	3	dermatol	dermatol	NOUN
dpc-2740	72	4	ther	ther	ADV
dpc-2740	72	5	.	.	PUNCT
dpc-2740	73	1	2022;7:183	2022;7:183	X
dpc-2740	73	2	.	.	PUNCT
dpc-2740	74	1	doi	doi	NOUN
dpc-2740	74	2	:	:	PUNCT
dpc-2740	74	3	10.29011/2575	10.29011/2575	NUM
dpc-2740	74	4	-8268.100183	-8268.100183	X
dpc-2740	74	5	.	.	PUNCT
dpc-2740	74	6	figure	figure	NOUN
dpc-2740	74	7	2	2	NUM
dpc-2740	74	8	.	.	PUNCT
dpc-2740	75	1	(	(	PUNCT
dpc-2740	75	2	a	a	DET
dpc-2740	75	3	,	,	PUNCT
dpc-2740	75	4	b	b	NOUN
dpc-2740	75	5	)	)	PUNCT
dpc-2740	75	6	clinical	clinical	ADJ
dpc-2740	75	7	picture	picture	NOUN
dpc-2740	75	8	at	at	ADP
dpc-2740	75	9	week	week	NOUN
dpc-2740	75	10	36	36	NUM
dpc-2740	75	11	,	,	PUNCT
dpc-2740	75	12	showing	show	VERB
dpc-2740	75	13	resolution	resolution	NOUN
dpc-2740	75	14	of	of	ADP
dpc-2740	75	15	the	the	DET
dpc-2740	75	16	cutaneous	cutaneous	ADJ
dpc-2740	75	17	lesions	lesion	NOUN
dpc-2740	75	18	.	.	PUNCT
dpc-2740	76	1	only	only	ADV
dpc-2740	76	2	slight	slight	ADJ
dpc-2740	76	3	onychopathy	onychopathy	ADJ
dpc-2740	76	4	is	be	AUX
dpc-2740	76	5	observed	observe	VERB
dpc-2740	76	6	.	.	PUNCT